GlassScriptPhysician profile
Jasper Yuen
NPI 1346900362
$5,036.50
in general payments reported to CMS, 2019-2025
39 companies · $1,824 in 2025
The $1,824 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $165 · 2023: $1,159 · 2024: $1,889 · 2025: $1,824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,871.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $706.66 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $661.96 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $580.83 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $570.50 | 2023-2025 | |
| Lilly USA, LLC | $460.04 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $271.43 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $224.33 | 2023-2025 | Repatha, Otezla, Otezla |
| Phathom Pharmaceuticals, INC. | $156.52 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $152.83 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.84 | 2023-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.89 | 2023-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $82.17 | 2024-2025 | |
| Optinose US, INC. | $73.34 | 2025 | |
| Axsome Therapeutics, INC. | $71.65 | 2025 | Auvelity |
| Pfizer INC. | $64.19 | 2022-2023 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $58.38 | 2023 | |
| Dexcom, INC. | $56.47 | 2023-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $54.71 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $52.41 | 2024-2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $51.64 | 2024-2025 | Tirosint, Licart, Flector |
| Astellas Pharma US INC | $43.26 | 2023 | Myrbetriq, Veozah |
| Seqirus USA INC | $42.96 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Lundbeck LLC | $40.34 | 2024 | Rexulti |
| Ucb, INC. | $35.35 | 2023 | Nayzilam |
| Paratek Pharmaceuticals, INC. | $34.51 | 2023-2024 | Nuzyra |
| Mannkind Corporation | $33.79 | 2023 | Afrezza |
| Merck Sharp & Dohme LLC | $30.96 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| Viiv Healthcare Company | $24.16 | 2025 | Apretude |
| Antares Pharma, INC. | $23.58 | 2023 | Xyosted, Tlando, Nocdurna |
| Tolmar, INC. | $23.37 | 2025 | Jatenzo |
| Janssen Pharmaceuticals, INC | $20.85 | 2023 | Spravato |
| Ars Pharmaceuticals Operations, INC. | $20.04 | 2025 | Neffy |
| Esperion Therapeutics, INC. | $18.37 | 2024 | Nexletol |
| Aimmune Therapeutics, INC. | $17.96 | 2025 | Zenpep |
| Gilead Sciences, INC. | $17.10 | 2025 | |
| Sanofi Pasteur INC. | $16.13 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $15.55 | 2024 | Eliquis |
| Renalytix Ai, INC. | $14.53 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Idorsia Pharmaceuticals US INC | $13.90 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasper Yuen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.